^* Library-free and machine learning-powered data analysis
with Spectronaut(®) 18 enables an industry-leading
Protein quantification and high throughput for DIA proteomics
* New joint research with the service platforms TrueDiscovery(®) and
TrueTarget(®) for contract research organizations demonstrates the quantitative
Precision and broad applicability of mass spectrometry proteomics for the
Biomarker discovery and drug development
* Biognosys’ iRT kit is the cornerstone of novel real-time
Performance monitoring from Bruker as part of ProteoScape(TM) analysis for
timsTOF instruments
ZURICH, Switzerland, and CAMBRIDGE, Massachusetts, Sept. 17, 2023 (GLOBE NEWSWIRE)
— Biognosys, a leading inventor and developer of mass spectrometry
(MS)-based proteomics solutions, today announced its participation in the World Congress
Human Proteome Organization (HUPO) from September 17th to 21st
(https://2023.hupo.org/) in Busan, South Korea.
During the Technological Advances session on Tuesday, September 19,
will Dr. Lukas Reiter, Chief Technology Officer of Biognosys, a keynote speech
Presentation entitled “Bottom-up Proteomics using DIA”.
with DIA) about the development, recent developments and the future of the
data-independent acquisition (DIA) in the MS
based proteomics. Biognosys will also present ten posters,
the technological innovations and new scientific data with its
introduce proprietary proteomics research services, software and kits.
Biognosys’ scientific expert team will be at booth #408
exhibit and offer software demonstrations.
Biognosys’ strategic partner, Bruker, will develop new concepts for the
Introduce the timsTOF platform and the Bruker ProteoScape(TM) software suite and
Synergies with Biognosys’ Spectronaut(®) software and iRT kit
to provide customers with expanded options for high-fidelity proteomics
with high throughput.
“I am excited that we have MS proteomics technology and solutions
Biognosys has been able to make significant progress that brings us closer again
to use the proteome for research, drug development and
to truly harness clinical decision-making,” commented Dr.
Lukas Reiter.?Our constantly improved software and our proven kits
enable users of key MS instruments to have state-of-the-art,
Hassle-free workflows for deep, reproducible proteomics research
to be carried out in-house. Our services for contract research organizations
offer our customers in the biopharma and diagnostics industry unparalleled
Precision and insights to drive biomarker discovery and development
of medication.”
Spectronaut(®) 18: Industry-leading depth, throughput and efficiency for DIA
Data analysis
Spectronaut 18, the latest version of Biognosys’ flagship product, offers a
Significantly further improved identification rate and quantification quality
as well as various new features that make DIA proteomics more efficient and
make it more scalable. Biognosys will present three posters at the HUPO congress
present the powerful applications of the Spectronaut 18 for the
present comprehensive quantification of proteomes. Among the notable ones
Innovations include the use of directDIA+(TM) for faster,
Library-free analysis and deep learning with DeepQuant to improve
Quantification of low-abundance proteins by a neuronal
Precursor set interference correction network.
TrueDiscovery(®): Proven precision for biomarker discovery in oncology
and neuroscience
Biognosys will present three posters detailing the research leading to the discovery
of biomarkers and the development of drugs is presented in
Collaboration with respected partners such as Genmab, Johns Hopkins University
School of Medicine, Stanford University and the University of Zurich
was carried out. The studies used the TrueDiscovery platform
Biognosys for unbiased proteomics and demonstrate overall quantitative
Precision, robustness and broad applicability of MS proteomics for the
oncological and neuroscientific research. A fourth poster rated
the technological and biological complementarity of TrueDiscovery and the
affinity-based platform Olink(®) Explore from Olink Proteomics AB for
Plasma proteomics.
TrueTarget(®): Efficient target unfolding and mapping of binding sites in
drug research
Biognosys’ TrueTarget platform leverages mass spectrometry
limited proteolysis (LiP-MS) to identify and validate
To facilitate drug targets. A first poster created in collaboration with
InterAx was created, demonstrating the unique capabilities of
TrueTarget in decoding the target of a G-protein-coupled
receptor (GPCR) antagonists, the mapping of its binding sites and the
Providing structural insights into the mechanism of action. A second
Poster, created in collaboration with Samsara Therapeutics, shows how the
Deconvolution of target proteins with TrueTarget and the subsequent
unbiased proteome profiling with TrueDiscovery
efficient identification and validation of target proteins and a better
Understanding biological systems enables the development of new therapies.
Biognosys and Bruker: Seamless workflows for dia-PASEF(®) and QC
timsTOF
To ensure optimal MS performance, Bruker introduces TwinScape(TM),
a digital twin for the timsTOF platform that works with the ProteoScape
Software is connected to real-time quality control (QC).
Biognosys iRT kit to support. The peptides in the iRT kit were carefully selected
Stability, sensitivity and retention time intervals optimized. This
iRT kit can now be used for system QC in ProteoScape proteomics software
Bruker can be used. Dr. Sira Echevarria, Head of Business Development –
Products at Biognosys, will be presented during Bruker’s HUPO lunch seminar on
Tuesday, September 19th, present how Spectronaut an improved
offers library-free proteome analysis for dia-PASEF with directDIA+.
Visit biognosys.com/hupo-2023 (https://biognosys.com/hupo-2023/) for
a complete overview of Biognosys’ presence at the congress
the HUPO. The posters will be available for download from Friday, September 22nd.
About Spectronaut(®)
Spectronaut is Biognosys’ flagship in the field of data analysis for
the data-independent acquisition in mass spectrometry-based proteomics.
The software uses advanced algorithms for search and artificial
Intelligence (AI) to transform data into actionable insights for the
transforming life science research. Spectronaut makes this possible
reproducible and precise quantification of thousands of proteins in one
single experiment and offers multidimensional insights into protein expression,
-function and structure in all major biological species and
Sample types. For more information, visit spectronaut.com
(http://spectronaut.com/).
About TrueDiscovery(®)
Biognosys’ TrueDiscovery platform provides integrated proteomics solutions
for the entire drug development.
TrueDiscovery is based on Hyper Reaction Monitoring (HRM)
Mass spectrometry, an advanced technology co-invented by Biognosys
patented technology for the quantification of proteins based on
independent data acquisition (Data Independent Acquisition; DIA).
TrueDiscovery is the only platform that searches the entire proteome to
Thousands of the most important proteins, including an unlimited number of
Proteoforms to quantify. The platform enables the most profound,
unadulterated profiling of tissue and biofluid proteomes with
unbeatable specificity at scale. The data generated is high
Measurements reproducible and easily transferable to clinical testing. The studies
can be carried out in a GLP-certified and GCP-compliant environment
become. For more information, visit truediscovery.bio
(http://truediscovery.bio/).
About TrueTarget(®)
Biognosys’ TrueTarget proteomics platform is a unique solution for
the most pressing challenges in early drug development by
They identify on- and off-targets to facilitate drug development in the
accelerate the entire pipeline and reduce risk.
TrueTarget is based on Limited Proteolysis Mass Spectrometry (LiP-MS), a
patented chemoproteomics technology co-developed by Biognosys.
TrueTarget is the only tool that detects structural changes throughout
Proteome studied at peptide level resolution making it unique
Insights into the binding of substances and the identification of targets
enabled.
The platform enables mechanisms of action to be clarified and uncovered
of unexpected toxicities. For more information, see
truetarget.bio (http://truetarget.bio/)
About Biognosys
At Biognosys, we believe that deep insights into the proteome are the key
groundbreaking discoveries that are changing science and life
improve. With our diverse portfolio of proteomics solutions
next generation, including research service platforms
TrueDiscovery(®), TrueTarget(®) and TrueSignature(®), our flagship
Software Spectronaut(®) and the PQ500(TM) kit, we make the proteome
capable of conducting research, drug development and clinical
to support decisions. Our solutions offer a multidimensional
View of protein expression, function and structure in all biological
Species and sample types. Use our unique, patented technologies
using high-resolution mass spectrometry to identify thousands of proteins
quantify depth and throughput with industry-leading precision. Through ours
Strategic partnership with Bruker (Nasdaq: BRKR) we do proteomics
accessible worldwide. For more information, visit biognosys.com
(http://www.biognosys.com/).
The source language in which the original text is published is
official and authorized version. Translations are becoming better
Communication included. Only the language version, the original
published is legally valid. Therefore, compare translations
the original language version of the publication.
°